DK2951290T3 - Fremgangsmåde til fremsilling retinale pigmentepitel (rpe) -celler ud fra inducerede pluripotente stamceller (ipscs) - Google Patents

Fremgangsmåde til fremsilling retinale pigmentepitel (rpe) -celler ud fra inducerede pluripotente stamceller (ipscs) Download PDF

Info

Publication number
DK2951290T3
DK2951290T3 DK14705645.1T DK14705645T DK2951290T3 DK 2951290 T3 DK2951290 T3 DK 2951290T3 DK 14705645 T DK14705645 T DK 14705645T DK 2951290 T3 DK2951290 T3 DK 2951290T3
Authority
DK
Denmark
Prior art keywords
cells
rpe
medium
cell
expression
Prior art date
Application number
DK14705645.1T
Other languages
English (en)
Inventor
Kapil Bharti
Janine Davis
Marc Ferrer-Alegre
Sheldon S Miller
Arvydas Maminishkis
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Application granted granted Critical
Publication of DK2951290T3 publication Critical patent/DK2951290T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/16—Activin; Inhibin; Mullerian inhibiting substance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/41—Hedgehog proteins; Cyclopamine (inhibitor)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)

Claims (31)

1. Fremgangsmåde til fremstilling af humane retinale pigmentepitel (RPE)-celler, hvilken fremgangsmåde omfatter: fremstilling af embryoide legemer ud fra inducerede humane pluripotente stamceller; dyrkning af de embryoide legemer i et første medium, som omfatter to Wnt-pathway-hæmmere og en Nodal-pathway-hæmmer; udpladning af de embryoide legemer på et matrigelovertrukket vævsdyrkningssubstrat i et andet medium, som (a) ikke omfatter basisk fibroblastvækstfaktor (bFGF); (b) omfatter en basisk fibro-blastvækstfaktor (bFGF)-hæmmer, de to Wnt-pathway-hæmmere og Nodal-pathway-hæmmeren; (c) omfatter 20 til 90 ng Noggin; og (d) omfatter 1 til 3% knockout-serumerstatning, til dannelse af differentierende RPE-celler; dyrkning af de differentierende RPE-celler i et tredje medium, som omfatter ACTIVIN A og Wnt3a; derpå dyrkning af cellerne i et fjerde, RPE-celle-, medium, som omfatter 5% føtalt serum, en kanonisk Wnt-hæmmer, en ikke-kanonisk Wnt-inducer samt Sonic- og FGF-pathway-hæmmere, idet der derved fremstilles humane RPE-celler.
2. Fremgangsmåde ifølge krav 1, hvor en af Wnt-pathway-hæmmerne er N-(2- aminoethyl)-5-chlorisoquinolin-8-sulfonamid (CK1-7), 3,5,7,8-tetrahydro-2-[4- (trifluormethyl)phenyl]-4H-thiopyrano[4,3-d]pyrimidin-4-on (XAV939), SFRP-1 ("secreted frizzled-related protein 1"), SFRP-2, SFRP-3, SFRP-4 eller SFRP-5.
3. Fremgangsmåde ifølge krav 1 eller krav 2, hvor det første medium omfatter 3,5 til 9 mM CK1-7.
4. Fremgangsmåde ifølge krav 1, hvor Nodal-pathway-hæmmeren er 4-(5- benzol[l,3]dioxol-5-yl-4-pyridin-2-yl-lH-imidazol-2-yl)-benzamid-hydrat, 4-[4-(1,3- benzodioxol-5-yl)-5-(2-pyridinyl)-lH-imidazol-2-yl]-benzamid-hydrat, 4-[4-(3,4- methylendioxyphenyl)-5-(2-pyridyl)-lH-imidazol-2-yl]-benzamid-hydrat (SB-431542), Lefty ("left-right determination factor") eller 2-(5-benzo[l,3]dioxol-5-yl-2-tert-butyl-3H-imidazol-4-yl)-6-methylpyridin-hydrochlorid-hydrat (SB-505124).
5. Fremgangsmåde ifølge krav 1 eller krav 4, hvor det første medium omfatter 3,5 til 9 mM SB-431542.
6. Fremgangsmåde ifølge et hvilket som helst af kravene 1-5, hvor det første medium er et retinacelleinducerende medium, som omfatter "Dulbecco's Modified Eagle's Medi- um" og F12 i et forhold på 1:1 i fravær af serum.
7. Fremgangsmåde ifølge et hvilket som helst af kravene 1-5, hvor bFGF-hæmmeren omfatter N-[(2R)-2,3-dihydroxypropoxy]-3,4-difluor-2-[(2-fluor-4-iodphenyl)amino]-benzamid (PD0325901), N-[2-[[4-(diethylamino)butyl]amino-6-(3,5- dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-N'-(l,l-dimethylethyl)urea (PD173074), 2-(2-amino-3-methoxyphenyl)-4H-l-benzopyran-4-on (PD 98059), l-tert-butyl-3-[6-(2,6-dichlorphenyl)-2-[[4-(diethylamino)butyl]amino]pyrido[2,3-d]pyrimidin-7-yl]urea (PD161570) eller 6-(2,6-dichlorphenyl)-2-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-8-methyl-pyrido[2,3-d]pyrimidin-7(8FI)-on-dihydrochlorid-hydrat (PD166285).
8. Fremgangsmåde ifølge et hvilket som helst af kravene 1-7, hvor det andet medium omfatter 0,5 til 2 mM PD0325901.
9. Fremgangsmåde ifølge et hvilket som helst af kravene 1-7, hvor det andet medium omfatter 3,5 til 9 mM CK1-7 og 3,5 til 9 mM SB-431542.
10. Fremgangsmåde ifølge krav 1, hvor det første medium omfatter 50 ng/ml DKK1 ("Dickkopf-related protein 1").
11. Fremgangsmåde ifølge et hvilket som helst af kravene 1-8, hvor det tredje medium omfatter 100 til 200 ng/ml ACTIVIN A.
12. Fremgangsmåde ifølge et hvilket som helst af kravene 1-11, hvor det tredje medium omfatter 75 til 150 ng/ml Wnt3a.
13. Fremgangsmåde ifølge et hvilket som helst af kravene 1-12, hvor den kanoniske Wnt-hæmmer er DKK1.
14. Fremgangsmåde ifølge krav 13, hvor det tredje medium omfatter 75 til 150 ng/ml DKK1.
15. Fremgangsmåde ifølge et hvilket som helst af kravene 1-14, hvor den ikke-kanoniske Wnt-induktor er Wnt5a.
16. Fremgangsmåde ifølge et hvilket som helst af kravene 1-15, hvor det fjerde medium omfatter 75 til 150 ng/ml Wnt5a, 75 til 150 ng/ml DKK1, 5 μΜ cyclopamin og/eller 10 μΜ SU5402.
17. Fremgangsmåde ifølge et hvilket som helst af kravene 1-15, hvor trin (a) omfat ter dyrkning af cellerne i nærvær af 1,5% knockout-serumerstatning.
18. Fremgangsmåde ifølge et hvilket som helst af kravene 1-17, hvor substratet er en transwell.
19. Fremgangsmåde ifølge et hvilket som helst af kravene 1-18, som omfatter ekspression af OCT4, SOX2, LIN28 og Nanog i en human føtal RPE-celle til fremstilling af de inducerede humane pluripotente stamceller.
20. Fremgangsmåde ifølge et hvilket som helst af kravene 1-19, hvor de inducerede humane pluripotente stamceller omfatter en nukleinsyre, som koder for en markør, der er operativt forbundet til en RPE-cellespecifik promotor.
21. Fremgangsmåde ifølge krav 20, hvor den retinaspecifikke promotor er en tyrosi-nasepromotor.
22. Fremgangsmåde ifølge et hvilket som helst af kravene 1-21, hvor de embryoide legemer dyrkes i det første medium i 48 timer.
23. Fremgangsmåde ifølge et hvilket som helst af kravene 1-22, hvor de embryoide legemer dyrkes i det andet medium i 18 til 24 døgn.
24. Fremgangsmåde ifølge krav 23, hvor de embryoide legemer dyrkes i det andet medium i tre uger.
25. Fremgangsmåde ifølge et hvilket som helst af kravene 1-24, hvor de differentierende RPE-celler dyrkes i det tredje medium i 18 til 24 døgn.
26. Fremgangsmåde ifølge krav 25, hvor de differentierende RPE-celler dyrkes i det tredje medium i tre uger.
27. Fremgangsmåde ifølge et hvilket som helst af kravene 1-26, hvor cellerne dyrkes i RPE-mediet i 12 til 16 døgn.
28. Fremgangsmåde ifølge krav 27, hvor cellerne dyrkes i RPE-mediet i to uger.
29. Fremgangsmåde ifølge et hvilket som helst af kravene 1-28, som yderligere omfatter bibeholdelse af RPE-cellerne i RPE-medium, der omfatter 5% føtalt serum.
30. Fremgangsmåde ifølge krav 29, som omfatter bibeholdelse af RPE-cellerne i RPE-medium, der omfatter 5% føtalt serum, i seks til otte uger.
31. Fremgangsmåde til bestemmelse af, om et middel af interesse øger differentieringen af RPE-celler, hvilken fremgangsmåde omfatter dyrkning af de embryoide legemer, der er fremstillet ud fra inducerede humane pluripotente stamceller omfattende en nukleinsyre, som koder for en første markør, der er operativt forbundet til en RPE-cellespecifik promotor, og omfattende en anden markør, der er operativt forbundet til en konstitutiv promotor, i et første medium, som omfatter to Wnt-pathway-hæmmere og en Nodal-pathway-hæmmer; udpladning af de embryoide legemer på et vævsdyrkningssubstrat i et andet medium, som (a) ikke omfatter basisk fibroblastvækstfaktor (bFGF); (b) omfatter en basisk fibro-blastvækstfaktor (bFGF)-hæmmer, de to Wnt-pathway-hæmmere og Nodal-pathway-hæmmeren; og (c) omfatter 20 til 90 ng Noggin, til dannelse af differentierende RPE-celler; dyrkning af de differentierende RPE-celler i et tredje medium, som omfatter ACTI- VIN A og Wnt3a; dyrkning af cellerne i et fjerde RPE-medium, som omfatter 5% føtalt serum, en kanonisk Wnt-hæmmer, en ikke-kanonisk Wnt-induktor samt Sonic- og FGF-pathway-hæmmere; idet der derved fremstilles humane RPE-celler, og i nærværelse af midlet af interesse; og evaluering af ekspressionen af den første markør i RPE-cellerne i sammenligning med ekspressionen af den anden markør, hvor en stigning i ekspressionen af den første markør i sammenligning med den anden markør indikerer, at midlet øger differentieringen af RPE-celler.
DK14705645.1T 2013-02-01 2014-01-31 Fremgangsmåde til fremsilling retinale pigmentepitel (rpe) -celler ud fra inducerede pluripotente stamceller (ipscs) DK2951290T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361759988P 2013-02-01 2013-02-01
PCT/US2014/014160 WO2014121077A2 (en) 2013-02-01 2014-01-31 METHOD FOR GENERATING RETINAL PIGMENT EPITHELIUM (RPE) CELLS FROM INDUCED PLURIPOTENT STEM CELLS (IPSCs)

Publications (1)

Publication Number Publication Date
DK2951290T3 true DK2951290T3 (da) 2018-01-22

Family

ID=50150802

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14705645.1T DK2951290T3 (da) 2013-02-01 2014-01-31 Fremgangsmåde til fremsilling retinale pigmentepitel (rpe) -celler ud fra inducerede pluripotente stamceller (ipscs)

Country Status (7)

Country Link
US (4) US20150368713A1 (da)
EP (2) EP3323884A1 (da)
JP (2) JP6426110B2 (da)
AU (2) AU2014212230B2 (da)
CA (1) CA2899865C (da)
DK (1) DK2951290T3 (da)
WO (1) WO2014121077A2 (da)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6200883B2 (ja) 2011-04-29 2017-09-20 ユニヴァーシティー オブ サザン カリフォルニア ポリマー基質上の幹細胞由来網膜色素上皮細胞の低温保存方法
AU2014363032A1 (en) 2013-12-11 2016-06-09 Pfizer Limited Method for producing retinal pigment epithelial cells
EP3174906A1 (en) 2014-08-01 2017-06-07 Massachusetts Institute Of Technology Modified alginates for anti-fibrotic materials and applications
CN107427534A (zh) 2014-12-30 2017-12-01 细胞治疗神经科学有限公司 治疗视网膜疾病的方法
IL314417A (en) 2014-12-30 2024-09-01 Cell Cure Neurosciences Ltd Examination of retinal pigment epithelial cell populations
JP6882981B2 (ja) 2014-12-30 2021-06-02 セル キュア ニューロサイエンシズ リミテッド Ｒｐｅ細胞集団およびそれを作製する方法
ES2865024T3 (es) * 2015-07-29 2021-10-14 Hadasit Med Res Service Producción a gran escala de células de epitelio pigmentario retiniano
JP6868608B2 (ja) * 2015-08-05 2021-05-12 セル キュア ニューロサイエンシズ リミテッド 網膜疾患の処置のための光受容体の調製
WO2017021973A1 (en) * 2015-08-05 2017-02-09 Cell Cure Neurosciences Ltd. Preparation of retinal pigment epithelium cells
JP6884354B2 (ja) * 2015-09-08 2021-06-09 大日本住友製薬株式会社 網膜組織の製造方法
AU2016321170B2 (en) 2015-09-08 2022-09-01 Fujifilm Cellular Dynamics Method for reproducible differentiation of clinical-grade retinal pigment epithelium cells
ES2922475T3 (es) 2015-09-08 2022-09-15 Sumitomo Pharma Co Ltd Método para producir células epiteliales pigmentarias de la retina
AU2016318774B2 (en) 2015-09-08 2022-08-18 FUJIFILM Cellular Dynamics, Inc. MACS-based purification of stem cell-derived retinal pigment epithelium
US10865381B2 (en) 2015-10-20 2020-12-15 FUJIFILM Cellular Dynamics, Inc. Multi-lineage hematopoietic precursor cell production by genetic programming
SG11201803342RA (en) 2015-11-01 2018-05-30 Massachusetts Inst Technology Modified alginates for anti-fibrotic materials and applications
WO2017132596A1 (en) * 2016-01-27 2017-08-03 Memorial Sloan-Kettering Cancer Center Differentiation of cortical neurons from human pluripotent stem cells
WO2017218507A1 (en) 2016-06-13 2017-12-21 Massachusetts Institute Of Technology Biocompatible zwitterionic polymer coatings and hydrogels for reducing foreign body response and fibrosis
US11105796B2 (en) * 2016-06-21 2021-08-31 Bio-Techne Corporation Methods for non-invasive profiling of stem cell differentiation
EP3491134B1 (en) 2016-08-01 2023-10-11 University of Pittsburgh - of The Commonwealth System of Higher Education Human induced pluripotent stem cells for high efficiency genetic engineering
CA3043174A1 (en) 2016-11-09 2018-05-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Tissue clamp and implantation method
US11458225B2 (en) 2016-11-09 2022-10-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 3D vascularized human ocular tissue for cell therapy and drug discovery
MX2019006576A (es) 2016-12-07 2019-08-21 Mayo Found Medical Education & Res Metodos y materiales para usar soportes de fibrina para trasplante de epitelio de pigmento retiniano.
CN106754718A (zh) * 2016-12-19 2017-05-31 胡其锐 一种人胚胎干细胞快速定向分化至视网膜色素上皮细胞的方法
CA3055706A1 (en) * 2017-03-08 2018-09-13 Sumitomo Dainippon Pharma Co., Ltd. Method for producing retinal pigment epithelial cells
CN106906178A (zh) * 2017-04-07 2017-06-30 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 培养上皮细胞的组合物及其保持上皮样细胞形态中的应用
CN110709504A (zh) 2017-06-05 2020-01-17 梅约医学教育与研究基金会 培养、增殖和分化干细胞的方法和材料
CA3090592A1 (en) * 2017-09-01 2019-03-07 Orig3N, Inc. Allogeneic car-t platform using hla-matched bank of ipscs, and related compositions, systems, and methods
WO2019090309A1 (en) 2017-11-06 2019-05-09 Massachusetts Institute Of Technology Anti-inflammatory coatings to improve biocompatibility of neurological implants
WO2019099552A1 (en) * 2017-11-14 2019-05-23 The J. David Gladstone Institutes Methods of generating retinal pigment epithelium (rpe)
EP4000568A1 (en) * 2017-12-29 2022-05-25 Cell Cure Neurosciences Ltd. Retinal pigment epithelium cell compositions
EP4186921A1 (en) * 2018-03-23 2023-05-31 The Trustees of Columbia University in the City of New York Gene editing for autosomal dominant diseases
EP3781675A1 (en) 2018-04-20 2021-02-24 FUJIFILM Cellular Dynamics, Inc. Method for differentiation of ocular cells and use thereof
EP3847245A1 (en) * 2018-09-07 2021-07-14 University of Southern California Cryopreservation of cell-seeded substrates and related methods
CN117982733A (zh) 2018-11-19 2024-05-07 美国政府(由卫生和人类服务部的部长所代表) 可生物降解的组织置换植入物及其用途
US20230072771A1 (en) 2019-10-30 2023-03-09 Astellas Institute For Regenerative Medicine Methods for producing retinal pigment epithelium cells
JP2023536210A (ja) 2020-05-29 2023-08-24 フジフィルム セルラー ダイナミクス，インコーポレイテッド 網膜色素上皮及び光受容体の二重層、並びにその使用
AU2021280343A1 (en) 2020-05-29 2022-12-08 FUJIFILM Cellular Dynamics, Inc. Retinal pigmented epithelium and photoreceptor dual cell aggregates and methods of use thereof
CN112980770B (zh) * 2021-03-03 2022-08-02 华中科技大学同济医学院附属协和医院 诱导人类多能干细胞定向内皮分化方法
EP4347795A1 (en) 2021-05-28 2024-04-10 The United States of America, as represented by The Secretary, Department of Health and Human Services Methods to generate macular, central and peripheral retinal pigment epithelial cells
AU2022282379A1 (en) 2021-05-28 2023-11-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Biodegradable tissue scaffold with secondary matrix to host weakly adherent cells
WO2023023256A1 (en) * 2021-08-18 2023-02-23 Oculogenex Inc. Aav-mediated gene transfer for retinopathy
WO2023146477A2 (en) * 2022-01-27 2023-08-03 Agency For Science, Technology And Research A method of differentiating an induced pluripotent stem cell into a retinal pigment epithelial cell, a retinal pigment epithelial cell and methods of using the retinal pigment epithelial cell
WO2023176906A1 (ja) 2022-03-16 2023-09-21 住友ファーマ株式会社 移植用媒体
US20230377685A1 (en) 2022-04-15 2023-11-23 Aspen Neuroscience, Inc. Methods of classifying the differentiation state of cells and related compositions of differentiated cells
WO2024079755A1 (en) * 2022-10-14 2024-04-18 Eyestem Research Private Limited A scalable method for producing retinal pigment epithelium (rpe) cells
CN117625536B (zh) * 2024-01-26 2024-04-30 中国人民解放军总医院第三医学中心 一种人视网膜色素上皮细胞的纯化、培养方法

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4956455A (en) 1984-03-05 1990-09-11 The Salk Institute For Biological Studies Bovine fibroblast growth factor
US5155214A (en) 1984-03-05 1992-10-13 The Salk Institute For Biological Studies Basic fibroblast growth factor
US5206347A (en) 1985-08-06 1993-04-27 La Jolla Cancer Research Foundation Isolation and use of receptors binding to a peptide column
US5439818A (en) 1985-09-12 1995-08-08 Scios Nova Inc. DNA encoding human recombinant basic fibroblast growth factor
US5091309A (en) 1986-01-16 1992-02-25 Washington University Sindbis virus vectors
CA1323293C (en) 1987-12-11 1993-10-19 Keith C. Backman Assay using template-dependent nucleic acid probe reorganization
DE68926504T2 (de) 1988-07-20 1996-09-12 David Segev Verfahren zur amplifizierung und zum nachweis von nukleinsäuresequenzen
US5217879A (en) 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
SG49267A1 (en) 1989-08-14 1998-05-18 Photogenesis Inc Surgical instrument and cell isolation and transplantation
US5427930A (en) 1990-01-26 1995-06-27 Abbott Laboratories Amplification of target nucleic acids using gap filling ligase chain reaction
US5750342A (en) 1990-06-11 1998-05-12 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands of tissue target
US5264563A (en) 1990-08-24 1993-11-23 Ixsys Inc. Process for synthesizing oligonucleotides with random codons
US6045791A (en) 1992-03-06 2000-04-04 Photogenesis, Inc. Retinal pigment epithelium transplantation
US6416998B1 (en) 1992-09-02 2002-07-09 Baylor College Of Medicine Plasmid encoding a modified steroid hormone
US5648211A (en) 1994-04-18 1997-07-15 Becton, Dickinson And Company Strand displacement amplification using thermophilic enzymes
WO1996002668A1 (en) 1994-07-15 1996-02-01 Azco Nobel N.V. Use of rna polymerase to improve nucleic acid amplification process
US5755785A (en) 1994-08-12 1998-05-26 The University Of South Florida Sutureless corneal transplantation method
US5763270A (en) 1995-06-07 1998-06-09 Genemedicine, Inc. Plasmid for delivery of nucleic acids to cells and methods of use
AT402203B (de) 1995-06-13 1997-03-25 Himmler Gottfried Dipl Ing Dr Verfahren zur transkriptionsfreien amplifizierung von nucleinsäuren
US5622699A (en) 1995-09-11 1997-04-22 La Jolla Cancer Research Foundation Method of identifying molecules that home to a selected organ in vivo
US5941250A (en) 1996-11-21 1999-08-24 University Of Louisville Research Foundation Inc. Retinal tissue implantation method
JP2001508302A (ja) 1997-01-10 2001-06-26 ライフ テクノロジーズ，インコーポレイテッド 胚性幹細胞血清置換
US6277820B1 (en) 1998-04-09 2001-08-21 Genentech, Inc. Method of dopaminergic and serotonergic neuron formation from neuroprogenitor cells
US7989425B2 (en) 2002-09-27 2011-08-02 Genexine Inc. Vaccine enhancing the protective immunity to hepatitis c virus using plasmid DNA and recombinant adenovirus
EP1681346A4 (en) 2003-08-29 2006-11-02 Soiken Inc HHV-6 OR HHV-7 DERIVED RECOMBINANT VIRUS VECTOR, METHOD FOR THE PRODUCTION THEREOF, METHOD FOR TRANSFORMING A HOST CELL USING THEREOF, TRANSFORMED HOST CELL AND GENE THERAPY METHOD USING THEREOF
US7682828B2 (en) 2003-11-26 2010-03-23 Whitehead Institute For Biomedical Research Methods for reprogramming somatic cells
CA2629522A1 (en) 2005-11-14 2007-05-18 Merial Limited Gene therapy for renal failure
EP3418297B1 (en) 2005-12-13 2023-04-05 Kyoto University Nuclear reprogramming factor
US8129187B2 (en) 2005-12-13 2012-03-06 Kyoto University Somatic cell reprogramming by retroviral vectors encoding Oct3/4. Klf4, c-Myc and Sox2
US8278104B2 (en) 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
US9133435B2 (en) 2007-01-18 2015-09-15 Riken Method for induction/differentiation into photoreceptor cell
EP2886646B1 (en) 2007-04-18 2019-08-14 Hadasit Medical Research Services & Development Limited Stem cell-derived retinal pigment epithelial cells
PT2209888T (pt) 2007-10-12 2020-01-17 Astellas Inst For Regenerative Medicine Métodos aperfeiçoados de produção de células rpe e composições de células rpe
US9683232B2 (en) 2007-12-10 2017-06-20 Kyoto University Efficient method for nuclear reprogramming
JP2009251867A (ja) 2008-04-04 2009-10-29 Canon Inc データ処理装置、データ処理方法、記憶媒体、プログラム
EP2279247B1 (en) 2008-04-22 2019-01-02 Regenerative Research Foundation Retinal pigment epithelial stem cells
WO2009134681A2 (en) 2008-04-30 2009-11-05 The Trustees Of The University Of Pennsylvania Aav7 viral vectors for targeted delivery of rpe cells
CN105802917A (zh) 2008-10-24 2016-07-27 威斯康星校友研究基金会 通过非病毒重编程获得的多潜能干细胞
WO2010144696A1 (en) 2009-06-11 2010-12-16 Burnham Institute For Medical Research Directed differentiation of stem cells
WO2011016588A1 (en) 2009-08-07 2011-02-10 Kyoto University Method of efficiently establishing induced pluripotent stem cells
WO2011028524A1 (en) * 2009-08-24 2011-03-10 Wisconsin Alumni Research Foundation Substantially pure human retinal progenitor, forebrain progenitor, and retinal pigment epithelium cell cultures and methods of making the same
US9200252B2 (en) 2009-10-06 2015-12-01 Snu R&Db Foundation Compositions for inducing differentiation into retinal cells from retinal progenitor cells or inducing proliferation of retinal cells comprising Wnt signaling pathway activators
IL301479A (en) 2009-11-17 2023-05-01 Astellas Inst For Regenerative Medicine Methods for preparing human RPE cells and pharmaceutical preparations of human RPE cells
WO2011090221A1 (en) 2010-01-22 2011-07-28 Kyoto University Method for improving induced pluripotent stem cell generation efficiency
EP2383333B1 (en) 2010-04-28 2015-05-27 Technische Universität Dresden Method for producing polarized retinal progenitor cells from pluripotent stem cells and their differentiation into retinal pigment epithelium cells
US8278620B2 (en) 2010-05-03 2012-10-02 Thermo Finnigan Llc Methods for calibration of usable fragmentation energy in mass spectrometry
AU2011352154A1 (en) 2010-12-30 2013-07-18 Anthrogenesis Corporation Methods for cryopreserving and encapsulating cells
JP6200883B2 (ja) 2011-04-29 2017-09-20 ユニヴァーシティー オブ サザン カリフォルニア ポリマー基質上の幹細胞由来網膜色素上皮細胞の低温保存方法
EP2780022B2 (en) 2011-11-14 2022-09-07 Astellas Institute for Regenerative Medicine Pharmaceutical preparations of human rpe cells and uses thereof
US10519422B2 (en) 2012-02-29 2019-12-31 Riken Method of producing human retinal pigment epithelial cells
ES2688019T3 (es) 2012-06-05 2018-10-30 The Regents Of The University Of California Métodos y composiciones para la producción acelerada de células epiteliales pigmentadas retinianas a partir de células pluripotentes
US9803679B1 (en) 2016-09-14 2017-10-31 Martin Eidinger Deformable fastening thread providing wedge-effect

Also Published As

Publication number Publication date
WO2014121077A3 (en) 2014-12-11
US20180291448A1 (en) 2018-10-11
CA2899865C (en) 2023-10-10
US10480031B2 (en) 2019-11-19
US20200095637A1 (en) 2020-03-26
AU2014212230A1 (en) 2015-08-20
WO2014121077A2 (en) 2014-08-07
US20150368713A1 (en) 2015-12-24
AU2014212230B2 (en) 2019-07-04
EP3323884A1 (en) 2018-05-23
JP2019017394A (ja) 2019-02-07
JP6426110B2 (ja) 2018-11-21
EP2951290B1 (en) 2017-11-29
US11441184B2 (en) 2022-09-13
AU2019236596A1 (en) 2019-10-17
JP2016512955A (ja) 2016-05-12
CA2899865A1 (en) 2014-08-07
EP2951290A2 (en) 2015-12-09
US20220389505A1 (en) 2022-12-08

Similar Documents

Publication Publication Date Title
US11441184B2 (en) Method for generating retinal pigment epithelium (RPE) cells from induced pluripotent stem cells (IPSCs)
JP6792844B6 (ja) 網膜色素上皮細胞の製造方法
ES2747803T3 (es) Método de diferenciación a nociceptores de células madre embrionarias humanas y sus usos
US20230323294A1 (en) Differentiation of cortical neurons from human pluripotent stem cells
CA2920287C (en) Method for producing dopaminergic neurons
WO2018164240A1 (ja) 網膜色素上皮細胞の製造方法
JP7558501B2 (ja) 移植用神経網膜の品質を評価する方法及び移植用神経網膜シート
CN113226387B (zh) 可生物降解的组织置换植入物及其用途
JP2023512453A (ja) 神経細胞を分化させる方法ならびに関連する組成物および使用方法
JP7421049B2 (ja) 糸球体ポドサイトの誘導方法、及び該誘導方法を用いた多能性幹細胞からのポドサイトの製造方法
Rak-Raszewska Investigating the nephrogenic potential of mouse embryonic stem cells and their derivatives
EA041083B1 (ru) Способ индукции дифференцировки плюрипотентных стволовых клеток in vitro